

This article was downloaded by:

On: 26 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

Synthesis of Some 2'-Fluoro-2'-Deoxy-3'-C-Ethynyl and 3'-C-Vinyl- β -d-Lyxofuranosyl Nucleosides

O. Moukha-chafiq^a; K. N. Tiwari^a; J. A. Secrist III^a

^a Southern Research Institute, Birmingham, Alabama, USA

To cite this Article Moukha-chafiq, O. , Tiwari, K. N. and Secrist III, J. A.(2005) 'Synthesis of Some 2'-Fluoro-2'-Deoxy-3'-C-Ethynyl and 3'-C-Vinyl- β -d-Lyxofuranosyl Nucleosides', *Nucleosides, Nucleotides and Nucleic Acids*, 24: 5, 713 — 715

To link to this Article: DOI: 10.1081/NCN-200060300

URL: <http://dx.doi.org/10.1081/NCN-200060300>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

SYNTHESIS OF SOME 2'-FLUORO-2'-DEOXY-3'-C-ETHYNYL AND 3'-C-VINYLB-D-LYXOFURANOSYL NUCLEOSIDES

O. Moukha-chafiq, K. N. Tiwari, and J. A. Secrist III □ Southern Research Institute, Birmingham, Alabama, USA

□ 1-(2-Fluoro-2-deoxy-β-D-arabinofuranosyl)uracil (**5**) and 1-(2-fluoro-2-deoxy-β-D-arabinofuranosyl)cytosine (**6**) were synthesized as reported earlier. Both of these compounds were converted into 2'-fluoro-2'-deoxy-3'-C-ethynyl and 3'-C-vinyl-β-D-lyxofuranosyl nucleosides (**16–19**) by a multistep sequence. All these new nucleosides were evaluated against seven human tumor cell lines *in vitro*.

INTRODUCTION

The search for nucleoside analogues which function as selective inhibitors of polymerases, and other enzymes for the control of viral diseases and cancer has been the subject of intense research.^[1] However, as some of these nucleosides also undergo enzymatic degradations, a number of modifications has been carried out on both the sugar portion and the heterocycle to circumvent these deactivating processes. Nucleoside analogues that are good substrates for cellular kinases, but are resistant to other host enzymes such as phosphorylases and deaminases are potentially important for the development of therapeutic agents.

One important discovery in this area is that the replacement of the hydroxyl in the sugar portion of the nucleosides with a fluorine results in nucleoside analogues which have been found to have interesting biological activities. Clofarabine (2-chloro-2'-fluoro-ara-A) (**1**) (Figure 1), for example, which has been synthesized in our laboratory,^[2] was found to have potent anti-leukemic activity and currently is in human clinical trials.

In addition, the 3'-alkyl or alkynyl branched nucleoside analogues have been reported to exhibit a potent antiviral and anti-cancer activity. Several years ago,

This investigation was supported by the National Cancer Institute, National Institute of Health (P01-CA34200). The authors are indebted to Drs. Bill Parker and Bill Waud for cytotoxicity data; Dr. James M. Riordan, Mr. Mark Richardson, and Ms. Joan Bearden for spectral data, and Ms. Stephanie Brannon for help in preparation of this poster.

Address correspondence to J. A. Secrist III, Southern Research Institute, Birmingham, AL, USA; E-mail: secrist@sri.org





FIGURE 1

1-(3-C-ethynyl- β -D-ribo-pentofuranosyl)cytosine (**2**) (Figure 1) was synthesized by Matsuda et al.^[3] and showed good activity against various human solid tumors. This compound is undergoing human clinical trials. On the basis of these considerations, we have prepared some 2'-fluoro-2'-deoxy-3'-C-ethynyl and 3'-C-vinyl- β -D-lyxofuranosyl nucleosides. The synthesis and biological data on these compounds are presented.

RESULTS AND DISCUSSION

Our route (Scheme 1) to this series was accomplished by preparing the 2'-fluoro-2'-deoxy- β -D-arabinofuranosyl nucleosides (**5**) and (**6**) following the synthetic pathway previously described.^[4] Protection of the primary alcohol of these nucleosides was carried out using *tert*-butyldimethylsilyl chloride in pyridine at room temperature for 3 h to lead to compounds (**7**) and (**8**) in 94 and 92% yields,



SCHEME 1 Conditions: (a) HBr/HOAc; (b) bis-silylated uracil or cytosine/ CCl_4 /reflux; (c) NH_3/MeOH , r. t.; (d) TBDMSCl/pyridine, r.t.; (e) BzCl/DMF, r.t.; (f) Dess-Martin periodinane/ CH_2Cl_2 ; (g) HCCMgBr or $\text{H}_2\text{CCHMgBr}$, THF, -78°C ; (h) TBAF/THF, r.t.; (i) NH_3/MeOH , r.t.

respectively. Benzoylation of amino group in cytosine nucleoside (**8**) with benzoic anhydride in DMF provided compound (**9**) in 91% yield.

We next investigated the oxidation of the secondary alcohol at C-2' position of (**8**) and (**9**) using CrO_3 -pyridine- Ac_2O or Ac_2O -DMSO mixtures. Attempts to prepare the desired ketonucleosides (**10**) and (**11**), however, failed because of their instability under these conditions. Only the α,β -unsaturated ketone resulting from the elimination of the base was observed.

As an alternative, we decided to use Dess-Martin periodinane. Thus, treatment of (**10**) and (**11**) with Dess-Martin periodinane (4.5 eq) in methylene chloride at 0°C during 10 h followed by addition, in situ, of ethynyl magnesium bromide or vinyl magnesium bromide in tetrahydrofuran at -78°C gave lyxo-adducts (**12**–**15**), respectively, with high stereoselectivity.

For the deblocking of these nucleosides, compounds (**12**) and (**13**) were treated with tetrabutylammonium fluoride in tetrahydrofuran to obtain compounds (**16**) and (**17**), respectively. On the other hand, compounds (**14**) and (**15**) were deblocked as in the case of nucleosides (**12**) and (**13**) and further treated with NH_3/MeOH to furnish quantitatively the desired nucleosides (**18**) and (**19**).

The structures of these compounds were confirmed by ^1H and ^{13}C -NMR and mass spectrometry along with elemental analysis. Nucleosides (**16**–**19**) were examined in vitro against a panel of human tumor cell lines. No marked cytotoxicity was noted. The antiviral tests of these nucleosides are still in progress.

REFERENCES

1. Nair, V.; Jahnke, T.S. Antiviral activities of isometric dideoxynucleosides of D- and L-related stereochemistry. *Antimicrob. Agents Chemother.* **1995**, *39*, 1017–1029.
2. Montgomery, J.A.; Shortancy-Fowler, A.T.; Clayton, S.D.; Riordan, J.M.; Secrist, J.A., III. *J. Med. Chem.* **1992**, *35*, 397–401.
3. Hattori, H.; Tanaka, M.; Fukushima, M.; Sasaki, T.; Matsuda, A. Nucleosides and nucleotides. 158. 1-(3-C-ethynyl- β -D-*ribo*-pentofuranosyl)cytosine, 1-(3-C-ethynyl- β -D-*ribo*-pentofuranosyl)uracil, and their nucleobase analogues as new potential multifunctional anti-tumor nucleosides with a broad spectrum of activity. *J. Med. Chem.* **1996**, *39*, 5005–5011.
4. Wilds, C.J.; Damha, M.J. 2'-deoxy-2'-fluoro- β -D-arabinonucleosides and oligonucleotides (2'F-ANA): synthesis and physicochemical studies. *Nucleic Acids Res.* **2000**, *28*, 3625–3635.